Predicting mortality, thrombus recurrence and persistence in patients with post-acute myocardial infarction left ventricular thrombus
Left ventricular thrombus (LVT) is a common complication of acute myocardial infarction and is associated with morbidity from embolic complications. Predicting which patients will develop death or persistent LVT despite anticoagulation may help clinicians identify high-risk patients. We developed a...
Gespeichert in:
Veröffentlicht in: | Journal of thrombosis and thrombolysis 2021-08, Vol.52 (2), p.654-661 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 661 |
---|---|
container_issue | 2 |
container_start_page | 654 |
container_title | Journal of thrombosis and thrombolysis |
container_volume | 52 |
creator | Yeung, Wesley Sia, Ching-Hui Pollard, Tom Leow, Aloysius Sheng-Ting Tan, Benjamin Yong-Qiang Kaur, Rajinderdeep Yeo, Tiong-Cheng Tay, Edgar Lik-Wui Yeo, Leonard Leong-Litt Chan, Mark Yan-Yee Loh, Joshua Ping-Yun |
description | Left ventricular thrombus (LVT) is a common complication of acute myocardial infarction and is associated with morbidity from embolic complications. Predicting which patients will develop death or persistent LVT despite anticoagulation may help clinicians identify high-risk patients. We developed a random forest (RF) model that predicts death or persistent LVT and evaluated its performance. This was a single-center retrospective cohort study in an academic tertiary center. We included 244 patients with LVT in our study. Patients who did not receive anticoagulation (n = 8) or had unknown (n = 31) outcomes were excluded. The primary outcome was a composite outcome of death, recurrent LVT and persistent LVT. We selected a total of 31 predictors collected at the point of LVT diagnosis based on clinical relevance. We compared conventional regularized logistic regression with the RF algorithm. There were 156 patients who had resolution of LVT and 88 patients who experienced the composite outcome. The RF model achieved better performance and had an AUROC of 0.700 (95% CI 0.553–0.863) on a validation dataset. The most important predictors for the composite outcome were receiving a revascularization procedure, lower visual ejection fraction (EF), higher creatinine, global wall motion abnormality, higher prothrombin time, higher body mass index, higher activated partial thromboplastin time, older age, lower lymphocyte count and higher neutrophil count. The RF model accurately identified patients with post-AMI LVT who developed the composite outcome. Further studies are needed to validate its use in clinical practice. |
doi_str_mv | 10.1007/s11239-020-02368-1 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2475093898</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2586212698</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-cf9bec16fc1c0c022fd65377097ad11d1840848fdbb25a35d3eac403c140589b3</originalsourceid><addsrcrecordid>eNp9kU9rFTEUxYMo9rX6BVxIwI2Ljt4kk5nJUor_oKALBXchk2TalJlkvMlU3gfwexvfqxVcuAiXkN85J9xDyDMGrxhA_zozxoVqgEM9ohsa9oDsmOxF07f820OyA8VVIwXIE3Ka8w0AKAX8MTkRQgyqA7UjPz-jd8GWEK_okrCYOZT9OS3XmJZxyxS93RB9tJ6a6OjqMYdcDvcQ6WpK8LFk-iOUa7qmXBpjt-Lpsk_WoAtmrthksAakSGc_FXpbBRjsNhu8j3lCHk1mzv7p3TwjX9-9_XLxobn89P7jxZvLxrZMlcZOavSWdZNlFixwPrlOir4H1RvHmGNDC0M7TG4cuTRCOuGNbUFY1oIc1CjOyMuj74rp--Zz0UvI1s-ziT5tWfO2l6DqboaKvvgHvUkbxvo7zeXQcca7A8WPlMWUM_pJrxgWg3vNQP8uSR9L0rUkfShJsyp6fme9jYt395I_rVRAHIFcn-KVx7_Z_7H9BbTWoCg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2586212698</pqid></control><display><type>article</type><title>Predicting mortality, thrombus recurrence and persistence in patients with post-acute myocardial infarction left ventricular thrombus</title><source>MEDLINE</source><source>SpringerLink (Online service)</source><creator>Yeung, Wesley ; Sia, Ching-Hui ; Pollard, Tom ; Leow, Aloysius Sheng-Ting ; Tan, Benjamin Yong-Qiang ; Kaur, Rajinderdeep ; Yeo, Tiong-Cheng ; Tay, Edgar Lik-Wui ; Yeo, Leonard Leong-Litt ; Chan, Mark Yan-Yee ; Loh, Joshua Ping-Yun</creator><creatorcontrib>Yeung, Wesley ; Sia, Ching-Hui ; Pollard, Tom ; Leow, Aloysius Sheng-Ting ; Tan, Benjamin Yong-Qiang ; Kaur, Rajinderdeep ; Yeo, Tiong-Cheng ; Tay, Edgar Lik-Wui ; Yeo, Leonard Leong-Litt ; Chan, Mark Yan-Yee ; Loh, Joshua Ping-Yun</creatorcontrib><description>Left ventricular thrombus (LVT) is a common complication of acute myocardial infarction and is associated with morbidity from embolic complications. Predicting which patients will develop death or persistent LVT despite anticoagulation may help clinicians identify high-risk patients. We developed a random forest (RF) model that predicts death or persistent LVT and evaluated its performance. This was a single-center retrospective cohort study in an academic tertiary center. We included 244 patients with LVT in our study. Patients who did not receive anticoagulation (n = 8) or had unknown (n = 31) outcomes were excluded. The primary outcome was a composite outcome of death, recurrent LVT and persistent LVT. We selected a total of 31 predictors collected at the point of LVT diagnosis based on clinical relevance. We compared conventional regularized logistic regression with the RF algorithm. There were 156 patients who had resolution of LVT and 88 patients who experienced the composite outcome. The RF model achieved better performance and had an AUROC of 0.700 (95% CI 0.553–0.863) on a validation dataset. The most important predictors for the composite outcome were receiving a revascularization procedure, lower visual ejection fraction (EF), higher creatinine, global wall motion abnormality, higher prothrombin time, higher body mass index, higher activated partial thromboplastin time, older age, lower lymphocyte count and higher neutrophil count. The RF model accurately identified patients with post-AMI LVT who developed the composite outcome. Further studies are needed to validate its use in clinical practice.</description><identifier>ISSN: 0929-5305</identifier><identifier>EISSN: 1573-742X</identifier><identifier>DOI: 10.1007/s11239-020-02368-1</identifier><identifier>PMID: 33389609</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Aged ; Anticoagulants - therapeutic use ; Blood clots ; Body mass index ; Cardiology ; Cell number ; Creatinine ; Death ; Heart ; Heart attacks ; Hematology ; Humans ; Leukocytes (neutrophilic) ; Lymphocytes ; Medicine ; Medicine & Public Health ; Morbidity ; Myocardial infarction ; Myocardial Infarction - complications ; Patients ; Prothrombin ; Retrospective Studies ; Risk groups ; Thromboplastin ; Thrombosis ; Ventricle ; Ventricular Function, Left</subject><ispartof>Journal of thrombosis and thrombolysis, 2021-08, Vol.52 (2), p.654-661</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-cf9bec16fc1c0c022fd65377097ad11d1840848fdbb25a35d3eac403c140589b3</citedby><cites>FETCH-LOGICAL-c419t-cf9bec16fc1c0c022fd65377097ad11d1840848fdbb25a35d3eac403c140589b3</cites><orcidid>0000-0002-3224-8954</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11239-020-02368-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11239-020-02368-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33389609$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yeung, Wesley</creatorcontrib><creatorcontrib>Sia, Ching-Hui</creatorcontrib><creatorcontrib>Pollard, Tom</creatorcontrib><creatorcontrib>Leow, Aloysius Sheng-Ting</creatorcontrib><creatorcontrib>Tan, Benjamin Yong-Qiang</creatorcontrib><creatorcontrib>Kaur, Rajinderdeep</creatorcontrib><creatorcontrib>Yeo, Tiong-Cheng</creatorcontrib><creatorcontrib>Tay, Edgar Lik-Wui</creatorcontrib><creatorcontrib>Yeo, Leonard Leong-Litt</creatorcontrib><creatorcontrib>Chan, Mark Yan-Yee</creatorcontrib><creatorcontrib>Loh, Joshua Ping-Yun</creatorcontrib><title>Predicting mortality, thrombus recurrence and persistence in patients with post-acute myocardial infarction left ventricular thrombus</title><title>Journal of thrombosis and thrombolysis</title><addtitle>J Thromb Thrombolysis</addtitle><addtitle>J Thromb Thrombolysis</addtitle><description>Left ventricular thrombus (LVT) is a common complication of acute myocardial infarction and is associated with morbidity from embolic complications. Predicting which patients will develop death or persistent LVT despite anticoagulation may help clinicians identify high-risk patients. We developed a random forest (RF) model that predicts death or persistent LVT and evaluated its performance. This was a single-center retrospective cohort study in an academic tertiary center. We included 244 patients with LVT in our study. Patients who did not receive anticoagulation (n = 8) or had unknown (n = 31) outcomes were excluded. The primary outcome was a composite outcome of death, recurrent LVT and persistent LVT. We selected a total of 31 predictors collected at the point of LVT diagnosis based on clinical relevance. We compared conventional regularized logistic regression with the RF algorithm. There were 156 patients who had resolution of LVT and 88 patients who experienced the composite outcome. The RF model achieved better performance and had an AUROC of 0.700 (95% CI 0.553–0.863) on a validation dataset. The most important predictors for the composite outcome were receiving a revascularization procedure, lower visual ejection fraction (EF), higher creatinine, global wall motion abnormality, higher prothrombin time, higher body mass index, higher activated partial thromboplastin time, older age, lower lymphocyte count and higher neutrophil count. The RF model accurately identified patients with post-AMI LVT who developed the composite outcome. Further studies are needed to validate its use in clinical practice.</description><subject>Aged</subject><subject>Anticoagulants - therapeutic use</subject><subject>Blood clots</subject><subject>Body mass index</subject><subject>Cardiology</subject><subject>Cell number</subject><subject>Creatinine</subject><subject>Death</subject><subject>Heart</subject><subject>Heart attacks</subject><subject>Hematology</subject><subject>Humans</subject><subject>Leukocytes (neutrophilic)</subject><subject>Lymphocytes</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Morbidity</subject><subject>Myocardial infarction</subject><subject>Myocardial Infarction - complications</subject><subject>Patients</subject><subject>Prothrombin</subject><subject>Retrospective Studies</subject><subject>Risk groups</subject><subject>Thromboplastin</subject><subject>Thrombosis</subject><subject>Ventricle</subject><subject>Ventricular Function, Left</subject><issn>0929-5305</issn><issn>1573-742X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kU9rFTEUxYMo9rX6BVxIwI2Ljt4kk5nJUor_oKALBXchk2TalJlkvMlU3gfwexvfqxVcuAiXkN85J9xDyDMGrxhA_zozxoVqgEM9ohsa9oDsmOxF07f820OyA8VVIwXIE3Ka8w0AKAX8MTkRQgyqA7UjPz-jd8GWEK_okrCYOZT9OS3XmJZxyxS93RB9tJ6a6OjqMYdcDvcQ6WpK8LFk-iOUa7qmXBpjt-Lpsk_WoAtmrthksAakSGc_FXpbBRjsNhu8j3lCHk1mzv7p3TwjX9-9_XLxobn89P7jxZvLxrZMlcZOavSWdZNlFixwPrlOir4H1RvHmGNDC0M7TG4cuTRCOuGNbUFY1oIc1CjOyMuj74rp--Zz0UvI1s-ziT5tWfO2l6DqboaKvvgHvUkbxvo7zeXQcca7A8WPlMWUM_pJrxgWg3vNQP8uSR9L0rUkfShJsyp6fme9jYt395I_rVRAHIFcn-KVx7_Z_7H9BbTWoCg</recordid><startdate>20210801</startdate><enddate>20210801</enddate><creator>Yeung, Wesley</creator><creator>Sia, Ching-Hui</creator><creator>Pollard, Tom</creator><creator>Leow, Aloysius Sheng-Ting</creator><creator>Tan, Benjamin Yong-Qiang</creator><creator>Kaur, Rajinderdeep</creator><creator>Yeo, Tiong-Cheng</creator><creator>Tay, Edgar Lik-Wui</creator><creator>Yeo, Leonard Leong-Litt</creator><creator>Chan, Mark Yan-Yee</creator><creator>Loh, Joshua Ping-Yun</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3224-8954</orcidid></search><sort><creationdate>20210801</creationdate><title>Predicting mortality, thrombus recurrence and persistence in patients with post-acute myocardial infarction left ventricular thrombus</title><author>Yeung, Wesley ; Sia, Ching-Hui ; Pollard, Tom ; Leow, Aloysius Sheng-Ting ; Tan, Benjamin Yong-Qiang ; Kaur, Rajinderdeep ; Yeo, Tiong-Cheng ; Tay, Edgar Lik-Wui ; Yeo, Leonard Leong-Litt ; Chan, Mark Yan-Yee ; Loh, Joshua Ping-Yun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-cf9bec16fc1c0c022fd65377097ad11d1840848fdbb25a35d3eac403c140589b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aged</topic><topic>Anticoagulants - therapeutic use</topic><topic>Blood clots</topic><topic>Body mass index</topic><topic>Cardiology</topic><topic>Cell number</topic><topic>Creatinine</topic><topic>Death</topic><topic>Heart</topic><topic>Heart attacks</topic><topic>Hematology</topic><topic>Humans</topic><topic>Leukocytes (neutrophilic)</topic><topic>Lymphocytes</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Morbidity</topic><topic>Myocardial infarction</topic><topic>Myocardial Infarction - complications</topic><topic>Patients</topic><topic>Prothrombin</topic><topic>Retrospective Studies</topic><topic>Risk groups</topic><topic>Thromboplastin</topic><topic>Thrombosis</topic><topic>Ventricle</topic><topic>Ventricular Function, Left</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yeung, Wesley</creatorcontrib><creatorcontrib>Sia, Ching-Hui</creatorcontrib><creatorcontrib>Pollard, Tom</creatorcontrib><creatorcontrib>Leow, Aloysius Sheng-Ting</creatorcontrib><creatorcontrib>Tan, Benjamin Yong-Qiang</creatorcontrib><creatorcontrib>Kaur, Rajinderdeep</creatorcontrib><creatorcontrib>Yeo, Tiong-Cheng</creatorcontrib><creatorcontrib>Tay, Edgar Lik-Wui</creatorcontrib><creatorcontrib>Yeo, Leonard Leong-Litt</creatorcontrib><creatorcontrib>Chan, Mark Yan-Yee</creatorcontrib><creatorcontrib>Loh, Joshua Ping-Yun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Databases</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of thrombosis and thrombolysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yeung, Wesley</au><au>Sia, Ching-Hui</au><au>Pollard, Tom</au><au>Leow, Aloysius Sheng-Ting</au><au>Tan, Benjamin Yong-Qiang</au><au>Kaur, Rajinderdeep</au><au>Yeo, Tiong-Cheng</au><au>Tay, Edgar Lik-Wui</au><au>Yeo, Leonard Leong-Litt</au><au>Chan, Mark Yan-Yee</au><au>Loh, Joshua Ping-Yun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predicting mortality, thrombus recurrence and persistence in patients with post-acute myocardial infarction left ventricular thrombus</atitle><jtitle>Journal of thrombosis and thrombolysis</jtitle><stitle>J Thromb Thrombolysis</stitle><addtitle>J Thromb Thrombolysis</addtitle><date>2021-08-01</date><risdate>2021</risdate><volume>52</volume><issue>2</issue><spage>654</spage><epage>661</epage><pages>654-661</pages><issn>0929-5305</issn><eissn>1573-742X</eissn><abstract>Left ventricular thrombus (LVT) is a common complication of acute myocardial infarction and is associated with morbidity from embolic complications. Predicting which patients will develop death or persistent LVT despite anticoagulation may help clinicians identify high-risk patients. We developed a random forest (RF) model that predicts death or persistent LVT and evaluated its performance. This was a single-center retrospective cohort study in an academic tertiary center. We included 244 patients with LVT in our study. Patients who did not receive anticoagulation (n = 8) or had unknown (n = 31) outcomes were excluded. The primary outcome was a composite outcome of death, recurrent LVT and persistent LVT. We selected a total of 31 predictors collected at the point of LVT diagnosis based on clinical relevance. We compared conventional regularized logistic regression with the RF algorithm. There were 156 patients who had resolution of LVT and 88 patients who experienced the composite outcome. The RF model achieved better performance and had an AUROC of 0.700 (95% CI 0.553–0.863) on a validation dataset. The most important predictors for the composite outcome were receiving a revascularization procedure, lower visual ejection fraction (EF), higher creatinine, global wall motion abnormality, higher prothrombin time, higher body mass index, higher activated partial thromboplastin time, older age, lower lymphocyte count and higher neutrophil count. The RF model accurately identified patients with post-AMI LVT who developed the composite outcome. Further studies are needed to validate its use in clinical practice.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>33389609</pmid><doi>10.1007/s11239-020-02368-1</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-3224-8954</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0929-5305 |
ispartof | Journal of thrombosis and thrombolysis, 2021-08, Vol.52 (2), p.654-661 |
issn | 0929-5305 1573-742X |
language | eng |
recordid | cdi_proquest_miscellaneous_2475093898 |
source | MEDLINE; SpringerLink (Online service) |
subjects | Aged Anticoagulants - therapeutic use Blood clots Body mass index Cardiology Cell number Creatinine Death Heart Heart attacks Hematology Humans Leukocytes (neutrophilic) Lymphocytes Medicine Medicine & Public Health Morbidity Myocardial infarction Myocardial Infarction - complications Patients Prothrombin Retrospective Studies Risk groups Thromboplastin Thrombosis Ventricle Ventricular Function, Left |
title | Predicting mortality, thrombus recurrence and persistence in patients with post-acute myocardial infarction left ventricular thrombus |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T19%3A57%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predicting%20mortality,%20thrombus%20recurrence%20and%20persistence%20in%20patients%20with%20post-acute%20myocardial%20infarction%20left%20ventricular%20thrombus&rft.jtitle=Journal%20of%20thrombosis%20and%20thrombolysis&rft.au=Yeung,%20Wesley&rft.date=2021-08-01&rft.volume=52&rft.issue=2&rft.spage=654&rft.epage=661&rft.pages=654-661&rft.issn=0929-5305&rft.eissn=1573-742X&rft_id=info:doi/10.1007/s11239-020-02368-1&rft_dat=%3Cproquest_cross%3E2586212698%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2586212698&rft_id=info:pmid/33389609&rfr_iscdi=true |